http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Critical Current Density and Thermal Stability with Asymmetric CoFeB/Ru/CoFeB Synthetic Free Layers
Tae Young Lee,Chiyui Ahn,Byoung-Chul Min,Boram Jeong,Soo Young Jang,Sang-Ho Lim,Jurgen Langer,Berthold Ocker,Wolfram Maass,Seung-Young Park,Younghun Jo,Kyung-Ho Shin 한국자기학회 2011 한국자기학회 학술연구발표회 논문개요집 Vol.2011 No.6
Heinen Jan,Schulz Tomek,Kl¨aui Mathias,Boulle Olivier,Malinowski Gregory,Swagten Henk,Koopmans Bert,Ulysse Christian,Faini Giancarlo,Ocker Berthold,Wrona Jerzy,Ahn Sung-Min,Nguyen Ngoc-Minh,Ravelosona 한국물리학회 2013 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.62 No.10
We determine in high anisotropy Pt/Co- and Ni/Co-based multilayer materials, which are candidates for high density storage applications, the contributions to the extraordinary Hall effect. In order to gain more insight into the physics underlying these processes, the dependence of the extraordinary Hall resistivity on the longitudinal resistivity is used to identify the skew scattering and the combined intrinsic and side jump effects when analyzing their variation with temperature. Furthermore, the influence of an additional amorphous CoFeB layer is shown, revealing a possibility to enhance the extraordinary Hall effect using this material.
Cho, Byoung Chul,Dy, Grace K.,Govindan, Ramaswamy,Kim, Dong-Wan,Pennell, Nathan A.,Zalcman, Gerard,Besse, Benjamin,Kim, Joo-Hang,Koca, Goekben,Rajagopalan, Prabhu,Langer, Simon,Ocker, Matthias,Nogai, Elsevier 2018 Lung cancer Vol.123 No.-
<P><B>Abstract</B></P> <P><B>Objectives</B></P> <P>This phase Ib/II study evaluated safety, pharmacokinetics, maximum tolerated dose (MTD), and efficacy of the pan-cyclin-dependent kinase inhibitor roniciclib with cisplatin-etoposide (CIS-ETOP) or carboplatin-etoposide (CARBO-ETOP) in patients with extensive-disease small-cell lung cancer (ED-SCLC).</P> <P><B>Patients and methods</B></P> <P>In this open-label, non-randomized study, patients with previously untreated ED-SCLC received roniciclib twice daily (BID) in a 3 days on/4 days off schedule. Cisplatin 75 mg/m<SUP>2</SUP> or carboplatin (AUC5) dose was administered on day 1, and etoposide 100 mg/m<SUP>2</SUP> on days 1–3, of 21-day cycles. Phase Ib used a dose-escalation design to define the MTD for phase II. Pharmacokinetics were assessed.</P> <P><B>Results</B></P> <P>Forty-three patients received treatment (roniciclib 2.5 mg BID [+ CARBO-ETOP, n = 4; + CIS-ETOP, n = 3] and roniciclib 5 mg BID [+ CARBO-ETOP, n = 24; + CIS-ETOP, n = 12]). The MTD of roniciclib was 5 mg BID with CARBO-ETOP or CIS-ETOP. Common adverse events were nausea (90.7%) and vomiting (69.8%). Roniciclib was readily absorbed following oral administration at the MTD (median t<SUB>max</SUB> 0.5–1 h), with a 30–40% reduction in exposure when co-administered with CARBO-ETOP or CIS-ETOP; administration of roniciclib had no effect on etoposide or platinum pharmacokinetics. The response rate was 81.4% (35/43) overall and 86.1% (31/36) in the pooled roniciclib 5 mg BID population (all partial responses).</P> <P><B>Conclusion</B></P> <P>Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy. An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Phase Ib/II study of ED-SCLC patients treated with roniciclib plus chemotherapy. </LI> <LI> Combination was well tolerated and readily absorbed across all dose combinations. </LI> <LI> No clinically relevant PK interactions were observed upon concomitant treatment. </LI> <LI> Promising efficacy of roniciclib plus chemotherapy, despite low patient numbers. </LI> <LI> Unfavorable benefit/risk balance from another study led to study termination. </LI> </UL> </P>